Novavax | NVAX - Loan Capital


Novavax reported $246.3M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
Adma Biologics USD 193.58M 124.25M Mar/2026
Agenus USD 153.98M 15.68M Mar/2026
AstraZeneca USD 26.01B 46M Jun/2026
BioCryst Pharmaceuticals USD 395.2M 33.48M Mar/2026
Cassava Sciences USD 0 0 Dec/2024
Geron USD 119.83M 286K Mar/2026
GlaxoSmithKline GBP 13.95B 65M Jun/2026
MannKind USD 548.07M 371K Mar/2026
Merck USD 46.67B 77M Mar/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Moderna USD 597M 6M Jun/2026
Novartis USD 37.45B 7.86B Mar/2026
Novavax USD 246.3M 200K Dec/2025
Pfizer USD 60.5B 70M Jun/2026
Sanofi EUR 14.65B 806M Jun/2026
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
TG Therapeutics USD 745.14M 499.5M Mar/2026